Literature DB >> 21934452

Continuous glucose monitoring during pregnancy in women with polycystic ovary syndrome.

Romana Dmitrovic1, Heather I Katcher, Allen R Kunselman, Richard S Legro.   

Abstract

OBJECTIVE: To estimate whether women with polycystic ovary syndrome (PCOS) will display ambient hyperglycemia (as measured by continuous glucose monitoring) early in pregnancy that progressively exacerbates with advancing pregnancy.
METHODS: This was a case-control study during singleton pregnancies of 17 women with PCOS and 17 healthy women. A 75-g oral glucose tolerance test (OGTT) followed by 24-hour continuous glucose monitoring was obtained four times throughout the pregnancy (visit 1: 6-10 weeks; visit 2: 12-16 weeks; visit 3: 24-28 weeks; visit 4: 34-38 weeks).
RESULTS: Eight women with PCOS (47%) and two women in the control group (12%) developed gestational diabetes mellitus (GDM) as defined by World Health Organization criteria. Women with PCOS had a higher area under the curve for glucose during the OGTT at visit 1, visit 2, and visit 3, and for insulin at visit 1, compared with the control group. No differences were found between groups for any of the continuous glucose monitoring parameters studied. The free androgen index significantly decreased over the course of the study in both groups with a stronger decrease in the PCOS group at visit 1 (P=.003), visit 2 (P=.07), and visit 3 (P=.04). The difference in birth weight between groups was not significant: 3,346 g in women with PCOS and 3,633 g in women in the control group, and there was no perinatal morbidity.
CONCLUSION: Women with PCOS are at increased risk for GDM, which manifests early in pregnancy and is detectable by OGTT. Serial 24-hour glucose monitoring did not reveal changes in glucose metabolism, although our sample size was small. Hyperandrogenemia improves with progressive pregnancy in women with PCOS. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21934452      PMCID: PMC3642370          DOI: 10.1097/AOG.0b013e31822c887f

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  23 in total

1.  The MiniMed continuous glucose monitoring system.

Authors:  J J Mastrototaro
Journal:  Diabetes Technol Ther       Date:  2000       Impact factor: 6.118

2.  Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.

Authors:  Eszter Vanky; Solhild Stridsklev; Runa Heimstad; Pål Romundstad; Kristin Skogøy; Odrun Kleggetveit; Sissel Hjelle; Philip von Brandis; Torunn Eikeland; Karin Flo; Kristin Flaten Berg; Gabor Bunford; Agnethe Lund; Cecilie Bjerke; Ingunn Almås; Ann Hilde Berg; Anna Danielson; Gulim Lahmami; Sven Magnus Carlsen
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

3.  Screening for gestational diabetes mellitus by a model based on risk indicators: a prospective study.

Authors:  Dorte M Jensen; Lars Mølsted-Pedersen; Henning Beck-Nielsen; Jes G Westergaard; Per Ovesen; Peter Damm
Journal:  Am J Obstet Gynecol       Date:  2003-11       Impact factor: 8.661

4.  Gestational diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

5.  Obstetric outcome in women with polycystic ovarian syndrome.

Authors:  M Mikola; V Hiilesmaa; M Halttunen; L Suhonen; A Tiitinen
Journal:  Hum Reprod       Date:  2001-02       Impact factor: 6.918

6.  Comparison of the criteria forgestational diabetes mellitus by NDDG and Carpenter and Coustan, and the outcomes of pregnancy.

Authors:  A Gokcel; T Bagis; E B Killicadag; E Tarim; N Guvener
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

7.  Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes.

Authors:  E Boland; T Monsod; M Delucia; C A Brandt; S Fernando; W V Tamborlane
Journal:  Diabetes Care       Date:  2001-11       Impact factor: 19.112

8.  Determinants of mild gestational hyperglycemia and gestational diabetes mellitus in a large dutch multiethnic cohort.

Authors:  Rob N M Weijers; Dick J Bekedam; Yvo M Smulders
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

9.  Pregnancy outcome in women with PCOS and in controls matched by age and weight.

Authors:  L Haakova; D Cibula; K Rezabek; M Hill; M Fanta; J Zivny
Journal:  Hum Reprod       Date:  2003-07       Impact factor: 6.918

10.  Continuous glucose monitoring for the evaluation and improved control of gestational diabetes mellitus.

Authors:  R Chen; Y Yogev; A Ben-Haroush; L Jovanovic; M Hod; M Phillip
Journal:  J Matern Fetal Neonatal Med       Date:  2003-10
View more
  5 in total

Review 1.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 2.  Obesity and PCOS: implications for diagnosis and treatment.

Authors:  Richard S Legro
Journal:  Semin Reprod Med       Date:  2012-10-16       Impact factor: 1.303

3.  Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.

Authors:  Tao Tao; Yi Zhang; Yu-Chen Zhu; Jia-Rong Fu; Yu-Ying Wang; Jie Cai; Jing-Yu Ma; Yu Xu; Yi-Ning Gao; Yun Sun; WuQiang Fan; Wei Liu
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

Review 4.  Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Jun Z Qin; Li H Pang; Mu J Li; Xiao J Fan; Ru D Huang; Hong Y Chen
Journal:  Reprod Biol Endocrinol       Date:  2013-06-26       Impact factor: 5.211

5.  Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.

Authors:  Richard S Legro; Silva A Arslanian; David A Ehrmann; Kathleen M Hoeger; M Hassan Murad; Renato Pasquali; Corrine K Welt
Journal:  J Clin Endocrinol Metab       Date:  2013-10-22       Impact factor: 5.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.